Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pittcon, PAI-NET Announce Co-Programming Venture

By Drug Discovery Trends Editor | January 29, 2009

The Pittsburgh Conference announced a co-operative venture with the Professionals’ Net Work in Advanced Instrumentation Society (PAI-NET). In addition to exhibiting at Pittcon 2009, which will be in Chicago, Illinois at McCormick Place South from March 8 to March 13, 2009, PAI-NET will be participating in the Pittcon 2010 Technical Program. 
 
This mutually beneficial relationship will permit both organizations to combine ongoing efforts to help achieve the common goal of advancing the chemical and laboratory sciences.

Pitttcon 2009 President Ed Ladner commented, ‘This is an excellent opportunity for PAI-NET and for Pittcon. Japan has always been a major contributor to the developments in analytical chemistry and analytical instrumentation. Pittcon is the perfect platform to assist PAI-NET in showcasing their latest products and technologies while enabling us to provide our conferees and exhibitors a view of the global contributions Japan is making in the field of science today.’ He added, ‘Their participation in the 2010 Technical Program will be a value-added event for our conferees and exhibitors.’

Kenji Kojima, the Secretary General of PAI-NET comments, ‘We exhibit every year at Pittcon to help promote our vision and to educate technicians in instrumental analysis and to help promote the spread of instrument analysis.’

Release Date: January 27, 2009
Source: Pittcon 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50